Synucleinopathies is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Synucleinopathies are a group of [neurodegenerative diseases[/[diseases[/[diseases[/[diseases[/diseases characterized by the pathological accumulation of misfolded [alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX-- (alpha-synuclein) protein in [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, nerve fibers, or glial cells.
[alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein--TEMP--/mechanisms)--FIX-- is a 140-amino acid presynaptic protein encoded by the SNCA gene that plays essential roles in synaptic vesicle trafficking, [neurotransmitter] release, and membrane remodeling.
In synucleinopathies, α-synuclein undergoes conformational changes, aggregating into oligomers and eventually insoluble fibrils that deposit as Lewy bodies, Lewy neurites, or glial cytoplasmic inclusions (GCIs), depending on the specific disease (Spillantini et al., 1997; Goedert et al., 2017) [1].
The major synucleinopathies include [Parkinson's Disease (PD)[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, [Dementia with Lewy Bodies (DLB)[/diseases/[dementia-lewy-bodies[/diseases/[dementia-lewy-bodies[/diseases/[dementia-lewy-bodies--TEMP--/diseases)--FIX--, [Multiple System Atrophy (MSA)[/diseases/[multiple-system-atrophy[/diseases/[multiple-system-atrophy[/diseases/[multiple-system-atrophy--TEMP--/diseases)--FIX--, and Pure Autonomic Failure (PAF). Additionally, [REM Sleep Behavior Disorder (RBD)[/diseases/[rem-sleep-behavior-disorder[/diseases/[rem-sleep-behavior-disorder[/diseases/[rem-sleep-behavior-disorder--TEMP--/diseases)--FIX-- is increasingly recognized as a prodromal synucleinopathy, with over 80% of iRBD patients eventually converting to an overt synucleinopathy (Iranzo et al., 2013). The collective prevalence of synucleinopathies exceeds 2% in individuals over age 65, making them among the most common neurodegenerative conditions worldwide [2].
Synucleinopathies are classified based on the predominant cell type affected and the morphology of α-synuclein inclusions:
¶ Lewy Body Diseases (LBDs)
In Lewy body diseases, α-synuclein aggregates primarily within [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, forming characteristic Lewy bodies (dense, spherical cytoplasmic inclusions) and Lewy neurites (thread-like deposits in neuronal processes) [3].
| Disease |
Key Clinical Features |
Primary Brain Regions Affected |
| [Parkinson's Disease (PD)[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- |
Motor symptoms (bradykinesia, rigidity, tremor), non-motor features (hyposmia, constipation, depression) |
[substantia nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra--TEMP--/brain-regions)--FIX--, locus coeruleus, dorsal motor nucleus of vagus |
| [Dementia with Lewy Bodies (DLB)[/diseases/[dementia-lewy-bodies[/diseases/[dementia-lewy-bodies[/diseases/[dementia-lewy-bodies--TEMP--/diseases)--FIX-- |
Cognitive fluctuations, visual hallucinations, parkinsonism, REM sleep behavior disorder |
Neocortex, limbic structures, brainstem |
| Parkinson's Disease Dementia (PDD) |
PD motor symptoms preceding dementia by ≥1 year |
Neocortex (secondary to brainstem-dominant onset) |
PD and DLB exist on a clinical and pathological continuum, distinguished primarily by the temporal relationship between motor and cognitive symptoms. The "one-year rule" is used clinically: if dementia occurs within one year of motor onset, the diagnosis is DLB; if later, PDD (McKeith et al., 2017) [4].
[MSA[/diseases/[msa[/diseases/[msa[/diseases/[msa--TEMP--/diseases)--FIX-- is distinguished from Lewy body diseases by the predominant accumulation of α-synuclein in oligodendrocytes (glial cells), forming glial cytoplasmic inclusions (GCIs), also called Papp-Lantos bodies (Papp et al., 1989). MSA is further subdivided into:
- MSA-P (Parkinsonian type): Predominantly striatonigral degeneration with akinesia, rigidity, and postural instability (poor levodopa response)
- MSA-C (Cerebellar type): Predominantly olivopontocerebellar atrophy with cerebellar ataxia, dysarthria, and oculomotor dysfunction
- Both subtypes: Feature prominent autonomic dysfunction (orthostatic hypotension, urogenital dysfunction)
Several conditions are recognized as prodromal or early-stage synucleinopathies:
- [REM Sleep Behavior Disorder (iRBD)[/diseases/[rem-sleep-behavior-disorder[/diseases/[rem-sleep-behavior-disorder[/diseases/[rem-sleep-behavior-disorder--TEMP--/diseases)--FIX--: Loss of normal REM sleep atonia with dream-enacting behavior; >80% convert to PD, DLB, or MSA over 10-15 years (Iranzo et al., 2013)
- Pure Autonomic Failure (PAF): Isolated autonomic nervous system degeneration with orthostatic hypotension; Lewy body pathology restricted to peripheral autonomic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--; ~34% phenoconvert to LBD or MSA (Singer et al., 2017)
- Isolated hyposmia: Olfactory dysfunction may precede motor symptoms by years in PD
¶ alpha-synuclein: Structure and Pathology
[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX-- is a 140-amino acid protein comprising three domains:
- N-terminal amphipathic region (residues 1-60): Contains lipid-binding α-helical repeats; mediates membrane association
- Central hydrophobic NAC domain (residues 61-95): Non-amyloid component; critical for aggregation propensity
- C-terminal acidic tail (residues 96-140): Highly charged; involved in protein-protein interactions and calcium binding
In its physiological state, α-synuclein is intrinsically disordered but adopts α-helical conformations when bound to synaptic vesicle membranes. It plays key roles in:
- SNARE complex assembly and [synaptic vesicle] recycling
- [dopamine[/entities/[dopamine[/entities/[dopamine[/entities/[dopamine--TEMP--/entities)--FIX-- metabolism and release
- Mitochondrial membrane dynamics
- Lipid metabolism
In synucleinopathies, α-synuclein undergoes a conformational shift from its native state to β-sheet-rich structures that self-assemble into oligomers and fibrils through a nucleation-dependent polymerization process (Lashuel et al., 2013). This process is modulated by:
- Post-translational modifications: Phosphorylation at Ser129 (found in >90% of Lewy body α-synuclein vs. ~4% of normal), ubiquitination, nitration, truncation
- Genetic mutations: SNCA point mutations (A53T, A30P, E46K, H50Q, G51D, A53E) and multiplications
- Environmental factors: Pesticides (rotenone, paraquat), heavy metals, oxidative stress
- Cellular conditions: Elevated [calcium], low pH, [oxidative stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX--, impaired [proteostasis]
A breakthrough in understanding synucleinopathy heterogeneity has been the discovery of α-synuclein strains — structurally distinct conformations of aggregated protein that confer different biological properties. Cryo-electron microscopy (cryo-EM) has revealed fundamentally different filament architectures in different diseases (Schweighauser et al., 2020; Yang et al., 2022):
| Disease |
Filament Structure |
Key Features |
| PD/DLB |
Lewy body-type folds |
Two protofilaments; longer twist periodicity (~108 nm) |
| MSA Type I |
MSA fold Type I |
Two protofilaments; shorter twist (~65 nm); distinct interface |
| MSA Type II |
MSA fold Type II |
Single protofilament; compact core |
These structural differences explain the clinically distinct phenotypes and may underlie the different cell-type tropism ([neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- vs. oligodendrocytes) observed across synucleinopathies. MSA α-synuclein strains are more potent at seeding aggregation in experimental models, consistent with the more aggressive clinical course of MSA (Peng et al., 2018) [5].
A defining feature of synucleinopathies is the [prion-like spreading[/mechanisms/[prion-like-spreading[/mechanisms/[prion-like-spreading[/mechanisms/[prion-like-spreading--TEMP--/mechanisms)--FIX-- of α through the nervous system. The Braak hypothesis proposes that PD pathology begins in the enteric nervous system and dorsal motor nucleus of the vagus nerve, ascending through the brainstem to reach the midbrain and [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- in a stereotypical pattern (Braak et al., 2003) [6].
Key evidence for prion-like propagation includes:
- Host-to-graft transmission: Lewy body pathology found in embryonic dopaminergic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- transplanted into PD patients, demonstrating cell-to-cell transfer (Kordower et al., 2008)
- Seeding and templating: Injection of preformed α-synuclein fibrils into rodent brains induces Lewy-body-like pathology that spreads along neuronal connections (Luk et al., 2012)
- Strain-specific propagation: Different α-synuclein strains show distinct tropism, spreading patterns, and toxicity profiles
- Seed amplification assays: RT-QuIC and PMCA assays can detect and amplify minute quantities of pathological α-synuclein seeds from CSF, skin, and other tissues, enabling molecular diagnosis (Siderowf et al., 2023)
The mechanisms of cell-to-cell transfer include:
- Exosome-mediated release and uptake via [extracellular vesicles[/mechanisms/[extracellular-vesicles[/mechanisms/[extracellular-vesicles[/mechanisms/[extracellular-vesicles--TEMP--/mechanisms)--FIX--
- Tunneling nanotubes
- Direct secretion and endocytosis
- Trans-synaptic transmission along neuronal circuits
The SNCA gene (chromosome 4q22.1) was the first gene linked to familial PD:
- Point mutations: A53T (the first identified), A30P, E46K, H50Q, G51D, A53E — each altering aggregation kinetics and strain properties
- Gene multiplications: Duplications cause PD; triplications cause early-onset PD with dementia (gene dosage effect)
- Risk variants: Common SNCA polymorphisms (Rep1 microsatellite, 3'-UTR variants) modulate expression levels and PD risk
- [GBA1[/genes/[gba[/genes/[gba[/genes/[gba--TEMP--/genes)--FIX--: Mutations in the glucocerebrosidase gene are the most common genetic risk factor for PD and DLB, impairing [lysosomal function] and promoting α-synuclein accumulation (Sidransky et al., 2009)
- [LRRK2[/genes/[lrrk2[/genes/[lrrk2[/genes/[lrrk2--TEMP--/genes)--FIX--: Gain-of-function mutations (e.g., G2019S) increase kinase activity, affecting vesicular trafficking and [autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy--TEMP--/entities)--FIX--
- [PARK2/Parkin] and [PINK1[/genes/[pink1[/genes/[pink1[/genes/[pink1--TEMP--/genes)--FIX--: Recessive mutations impair [mitophagy[/mechanisms/[mitophagy[/mechanisms/[mitophagy[/mechanisms/[mitophagy--TEMP--/mechanisms)--FIX--, causing early-onset parkinsonism
- COQ2: Recessive mutations associated with MSA in certain populations
- **[APOE[/genes/[apoe[/genes/[apoe[/genes/[apoe--TEMP--/genes)--FIX--
- PMCA (Protein Misfolding Cyclic Amplification): Can distinguish PD/DLB seeds from MSA seeds based on kinetics and fluorescence profiles
- Peripheral tissue testing: α-synuclein SAAs in skin biopsies, olfactory mucosa, and submandibular gland offer minimally invasive diagnosis
- DaTSCAN (DAT-SPECT): Demonstrates dopamine transporter deficit, confirming nigrostriatal degeneration in PD, DLB, and MSA-P
- [amyloid PET[/entities/[amyloid-pet[/entities/[amyloid-pet[/entities/[amyloid-pet--TEMP--/entities)--FIX--: Helps distinguish DLB (often amyloid-negative) from [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--
- Cardiac MIBG scintigraphy: Reduced cardiac sympathetic innervation distinguishes Lewy body diseases from MSA
- MRI: Characteristic patterns include putaminal atrophy (MSA-P), "hot cross bun" sign in pons (MSA-C), and cortical atrophy patterns (DLB)
- [Neurofilament light chain ([NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX--: Elevated in MSA, moderate in PD; useful for differential diagnosis
- [p-tau217[/entities/[p-tau217[/entities/[p-tau217[/entities/[p-tau217--TEMP--/entities)--FIX-- and [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- ratios: Help exclude AD co-pathology
- α-synuclein species: Total, phosphorylated (pS129), and aggregated forms in CSF and blood
The 2023 NSD (Neuronal Synuclein Disease) Biological Staging proposal advocates anchoring the biological definition of synucleinopathies in the presence of pathological α-synuclein (detected by SAAs), rather than clinical phenotype alone, paralleling the AT(N) framework for [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- (Höglinger et al., 2024) [7].
¶ Cross-Seeding and Co-Pathologies
Synucleinopathies rarely occur in isolation. There is extensive co-pathology with other proteinopathies:
- α-Synuclein and [Tau[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein--TEMP--/entities)--FIX--: Co-localize in Lewy bodies; α-synuclein promotes tau] hyperphosphorylation and both proteins can cross-seed each other's aggregation (Giasson et al., 2003)
- α-Synuclein and [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX--: [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- promotes α-synuclein aggregation; ~50% of DLB patients have significant Alzheimer's co-pathology
- α-Synuclein and [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX--: Co-pathology reported in some PD and DLB cases, particularly in the amygdala
- [APOE4[/diseases/[apoe4[/diseases/[apoe4[/diseases/[apoe4--TEMP--/diseases)--FIX--: Exacerbates α and worsens cognitive decline in DLB
This extensive cross-seeding has led to the concept of "complex proteinopathies," where multiple misfolded proteins interact synergistically to drive neurodegeneration [8].
Several immunotherapeutic strategies target α-synuclein:
- Prasinezumab: Monoclonal antibody targeting aggregated α-synuclein; Phase 2 trials showed trend toward slowing motor progression in PD (Pagano et al., 2022)
- Cinpanemab: Targeted N-terminus of α-synuclein; Phase 2 did not meet primary endpoints; discontinued
- Active immunization (PD01A, PD03A): Peptide vaccines designed to elicit anti-α-synuclein antibodies; early phase trials ongoing
- [GLP-1 receptor agonists[/treatments/[glp1-receptor-agonists[/treatments/[glp1-receptor-agonists[/treatments/[glp1-receptor-agonists--TEMP--/treatments)--FIX--: Emerging evidence for neuroprotection in PD; lixisenatide and exenatide in clinical trials
- LRRK2 inhibitors: DNL201, BIIB122 targeting kinase activity in LRRK2+ and sporadic PD
- GBA1-targeted therapies: Ambroxol (GCase chaperone), venglustat (GCS inhibitor) for GBA1-PD
- Anle138b: Small molecule that blocks α-synuclein oligomer formation
- [Antisense oligonucleotides (ASOs)[/treatments/[antisense-oligonucleotide-therapy[/treatments/[antisense-oligonucleotide-therapy[/treatments/[antisense-oligonucleotide-therapy--TEMP--/treatments)--FIX--: Designed to reduce SNCA expression; ION464 in Phase 1 for MSA
- AAV-mediated gene therapy: Delivery of [GDNF[/entities/[gdnf[/entities/[gdnf[/entities/[gdnf--TEMP--/entities)--FIX-- or AADC to enhance dopaminergic function
- [CRISPR-based approaches[/treatments/[crispr-gene-editing[/treatments/[crispr-gene-editing[/treatments/[crispr-gene-editing--TEMP--/treatments)--FIX--: Experimental strategies to silence SNCA or correct mutations
- [mitophagy[/mechanisms/[mitophagy[/mechanisms/[mitophagy[/mechanisms/[mitophagy--TEMP--/mechanisms)--FIX-- enhancement: Targeting PINK1/Parkin pathway to clear damaged [mitochondria[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics--TEMP--/entities)--FIX--
- [autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy--TEMP--/entities)--FIX-- activation: [mTOR[/mechanisms/[mtor-neurodegeneration[/mechanisms/[mtor-neurodegeneration[/mechanisms/[mtor-neurodegeneration--TEMP--/mechanisms)--FIX-- inhibitors, [TFEB[/entities/[tfeb[/entities/[tfeb[/entities/[tfeb--TEMP--/entities)--FIX-- activators to enhance clearance
- Iron chelation: Deferiprone targeting [iron accumulation] in substantia nigra
- [Deep brain stimulation[/treatments/[deep-brain-stimulation[/treatments/[deep-brain-stimulation[/treatments/[deep-brain-stimulation--TEMP--/treatments)--FIX--: Symptomatic treatment for advanced PD; does not modify α
¶ Animal and Cellular Models
- SNCA transgenic mice: Overexpression of human wild-type or mutant α-synuclein; reproduce aspects of Lewy-like pathology
- BAC-transgenic models: Bacterial artificial chromosome models with full human SNCA locus
- AAV-α-synuclein models: Viral vector-mediated overexpression enabling targeted regional expression
- GBA1 mutant models: Knock-in models of GBA1 mutations developing age-dependent synucleinopathy
Injection of preformed α-synuclein fibrils (PFFs) into rodent brains has become a standard model:
- Recapitulates progressive spreading pathology along neural circuits
- Strain-dependent patterns of pathology and cell death
- Enables testing of anti-propagation therapies
- iPSC-derived [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--: From PD and DLB patients, including SNCA, GBA1, and LRRK2 mutation carriers
- Brain organoids: 3D culture systems modeling α
- α-Synuclein PET tracers: Under development but challenging due to low aggregate density compared to tau] or [amyloid]
| Disease |
Estimated Prevalence |
Mean Age of Onset |
Median Survival from Diagnosis |
| [PD] |
1-2% over age 60 |
60-65 years |
15-20 years |
| [DLB] |
0.4% over age 65 |
65-70 years |
5-8 years |
| [MSA[/diseases/[msa[/diseases/[msa[/diseases/[msa--TEMP--/diseases)--FIX-- |
3-5 per 100,000 |
55-60 years |
6-10 years |
| PAF |
Rare (<1 per 100,000) |
50-60 years |
Variable; many phenoconvert |
| [iRBD] |
1-2% over age 60 |
60-70 years |
N/A (prodromal) |
- α-Synuclein PET tracers: Development of PET ligands that can image α-synuclein deposits in vivo, analogous to existing [amyloid PET[/entities/[amyloid-pet[/entities/[amyloid-pet[/entities/[amyloid-pet--TEMP--/entities)--FIX-- and tau PET tracers
- Biological staging: Implementation of SAA-based biological definitions enabling earlier diagnosis and clinical trial enrichment
- Strain-specific therapies: Designing interventions that target specific pathological conformations of α-synuclein
- Peripheral origins: Investigating the [Gut-Brain Axis[/entities/[gut-brain-axis[/entities/[gut-brain-axis[/entities/[gut-brain-axis--TEMP--/entities)--FIX-- as a starting point for α ([Gut-Brain Axis)
- Digital biomarkers: Wearable devices and smartphone-based monitoring for early detection and progression tracking
- Combination therapies: Multi-target approaches addressing both α and downstream neuroinflammatory and neurodegenerative cascades
- [Antisense Oligonucleotide Therapy[/treatments/[antisense-oligonucleotide-therapy[/treatments/[antisense-oligonucleotide-therapy[/treatments/[antisense-oligonucleotide-therapy--TEMP--/treatments)--FIX--
- [Crispr Gene Editing[/treatments/[crispr-gene-editing[/treatments/[crispr-gene-editing[/treatments/[crispr-gene-editing--TEMP--/treatments)--FIX--
- [Deep Brain Stimulation[/treatments/[deep-brain-stimulation[/treatments/[deep-brain-stimulation[/treatments/[deep-brain-stimulation--TEMP--/treatments)--FIX--
- [Glp1 Receptor Agonists[/treatments/[glp1-receptor-agonists[/treatments/[glp1-receptor-agonists[/treatments/[glp1-receptor-agonists--TEMP--/treatments)--FIX--
- [All Mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms
The study of Synucleinopathies has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R. & Goedert, M. (1997]. alpha-synuclein in Lewy bodies. Nature, 388(6645), 839-840. PubMed)
- [Goedert, M., Jakes, R. & Spillantini, M.G. (2017]. The Synucleinopathies: Twenty Years On. Journal of Parkinson's Disease, 7(s1), S51-S69. PubMed)
- [Iranzo, A., Tolosa, E., Gelpi, E., et al. (2013]. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder. The Lancet Neurology, 12(5), 443-453. PubMed)
- [McKeith, I.G., Boeve, B.F., Dickson, D.W., et al. (2017]. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report. Neurology, 89(1), 88-100. PubMed)
- [Papp, M.I., Kahn, J.E. & Lantos, P.L. (1989]. Glial cytoplasmic inclusions in the CNS of patients with Multiple System Atrophy. Journal of the Neurological Sciences, 94(1-3), 79-100. PubMed)
- [Lashuel, H.A., Overk, C.R., Oueslati, A. & Masliah, E. (2013]. The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nature Reviews Neuroscience, 14(1), 38-48. PubMed)
- [Schweighauser, M., Shi, Y., Tarutani, A., et al. (2020]. Structures of α-synuclein filaments from Multiple System Atrophy. Nature, 585(7825), 464-469. PubMed)
- [Yang, Y., Shi, Y., Schweighauser, M., et al. (2022]. Structures of α-synuclein filaments from human brains with Lewy pathology. Nature, 610(7933), 791-795. PubMed)
- [Braak, H., Del Tredici, K., Rüb, U., de Vos, R.A.I., Jansen Steur, E.N.H. & Braak, E. (2003]. Staging of brain pathology related to sporadic Parkinson's Disease. Neurobiology of Aging, 24(2), 197-211. PubMed)
- [Kordower, J.H., Chu, Y., Hauser, R.A., Freeman, T.B. & Olanow, C.W. (2008]. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's Disease. Nature Medicine, 14(5), 504-506. PubMed)
- [Luk, K.C., Kehm, V., Carroll, J., et al. (2012]. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science, 338(6109), 949-953. PubMed)
- [Siderowf, A., Concha-Marambio, L., Lafontant, D.E., et al. (2023]. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification. JAMA Neurology, 80(4), 407-414. PubMed)
- [Sidransky, E., Nalls, M.A., Aasly, J.O., et al. (2009]. Multicenter analysis of glucocerebrosidase mutations in Parkinson's Disease. New England Journal of Medicine, 361(17), 1651-1661. PubMed)
- [Peng, C., Gathagan, R.J., Covell, D.J., et al. (2018]. Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies. Nature, 557(7706), 558-563. PubMed)
- PubMed
- [Pagano, G., Taylor, K.I., Anzures-Cabrera, J., et al. (2022]. Trial of prasinezumab in early-stage Parkinson's Disease. New England Journal of Medicine, 387(5), 421-432. PubMed)
- [Singer, W., Berini, S.E., Sandroni, P., et al. (2017]. Pure autonomic failure: Predictors of conversion to clinical CNS involvement. Neurology, 88(12), 1129-1136. PubMed)
- [Höglinger, G.U., Adler, C.H., Berg, D., et al. (2024]. A biological classification of Parkinson's Disease: the SynNeurGe research diagnostic criteria. The Lancet Neurology, 23(2), 191-204. PubMed)
🟡 Moderate Confidence
| Dimension |
Score |
| Supporting Studies |
18 references |
| Replication |
33% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 46%